Top
image credit: Adobe Stock

Intra-Cellular shares rise on depression study’s success

March 28, 2023

Category:

Shares of Intra-Cellular Therapies rocketed up Tuesday morning, after the New York-based biotechnology company unveiled positive clinical trial results for a depression medication that some analysts called a “clear win.”

The medication, known scientifically as lumateperone and commercially as Caplyta, has already received Food and Drug Administration approval to treat schizophrenia as well as the depressive episodes associated with multiple types of bipolar disorder. But Intra-Cellular has been trying to broaden the drug’s use, and in late 2020 amended a late-stage study that initially focused on just bipolar depression to also include patients with major depressive disorder.

Read More on Biopharma Dive